deferoxamine has been researched along with Cardiac Failure in 47 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effects of the iron chelator deferoxamine on the functional and structural manifestations of iron-induced cardiac dysfunction, we measured cardiac power, left ventricular systolic, and diastolic function as (dP/dt)max and (dP/dt)min, respectively, and left ventricular and septal wall thickness in isolated heart preparations derived from the Mongolian gerbil model of iron overload." | 7.72 | Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| "Reversal of arrhythmia to sinus rhythm was noted in all patients." | 5.56 | Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 5.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 5.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| " In thalassemia major patients, combined therapy with desferrioxamine and deferiprone has maximized tissue iron removal and may reduce the overall occurrence of hemosiderotic heart failure." | 3.73 | Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia. ( Aessopos, A; Andriopoulos, P; Deftereos, S; Farmakis, D; Moyssakis, I; Polonifi, K; Tsironi, M, 2005) |
| "The incidence of cardiomyopathy was monitored in a 6-year follow-up study involving 56 transfused thalassemia patients treated with deferoxamine (DFO), deferiprone (L1) or their combination." | 3.73 | Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2006) |
| "To evaluate the effects of the iron chelator deferoxamine on the functional and structural manifestations of iron-induced cardiac dysfunction, we measured cardiac power, left ventricular systolic, and diastolic function as (dP/dt)max and (dP/dt)min, respectively, and left ventricular and septal wall thickness in isolated heart preparations derived from the Mongolian gerbil model of iron overload." | 3.72 | Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| "Strict lifelong adherence to the standard transfusion and deferoxamine therapy reduces considerably the occurrence of heart failure, LV dysfunction and pericarditis, prevents early heart failure and pulmonary hypertension, but does not eliminate completely cardiac disease in patients with thalassemia major." | 3.72 | Cardiac status in well-treated patients with thalassemia major. ( Aessopos, A; Diamanti-Kandaraki, E; Farmakis, D; Fragodimitri, C; Hatziliami, A; Joussef, J; Karabatsos, F; Karagiorga, M; Meletis, J; Mitilineou, E, 2004) |
| "Deferoxamine is still today the only preventive and curative treatment of transfusional hemochromatosis." | 3.68 | [Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-A-Cath)]. ( Clairicia, M; de Montalembert, M; Girot, R; Hannedouche, T; Jan, D; Sidi, D, 1992) |
| "Treatment with deferasirox significantly improves left ventricular function." | 2.77 | Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. ( Brevi, F; Cappellini, MD; Cassinerio, E; Graziadei, G; Milazzo, A; Pattoneri, P; Pedrotti, P; Roghi, A; Zanaboni, L, 2012) |
| "Thalassemia is anemia of variable severity, arising from mutations of genes encoding the hemoglobin alpha and beta chains." | 2.44 | Mechanisms of and obstacles to iron cardiomyopathy in thalassemia. ( Chang, JS; Lin, HS; Peng, CT; Tsai, CH; Wu, KH, 2008) |
| "Reversal of arrhythmia to sinus rhythm was noted in all patients." | 1.56 | Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020) |
| "Juvenile hemochromatosis is the most severe form of iron overloading phenotype." | 1.48 | Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report. ( Cooray, SD; Hamblin, PS; Heerasing, NM; Leet, AS; McDonald, CJ; McLean, CA; McNamara, E; Roberts, SK; Selkrig, LA; Subramaniam, VN, 2018) |
| "In patients with thalassemia major (TM) who are non-compliant with long-term desferrioxamine (DFO) chelation, survival is limited mainly because of cardiac complications of transfusional hemosiderosis." | 1.33 | Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. ( Aessopos, A; Andriopoulos, P; Deftereos, S; Farmakis, D; Meletis, J; Tsironi, M, 2005) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 1.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 1.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| "A 21-year-old woman with beta-thalassemia major (beta-TM) and GH deficiency developed end-stage heart failure, New York Heart Association (NYHA) functional class IV, within 3 months after withdrawal of recombinant human growth hormone (GH)." | 1.32 | Is growth hormone deficiency contributing to heart failure in patients with beta-thalassemia major? ( Erfurth, EM; Holmer, H; Kornhall, B; Nilsson, PG, 2004) |
| "Juvenile haemochromatosis is a rare inborn error of iron metabolism with clinical manifestations before 30 years of age." | 1.30 | Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease. ( Cox, TM; Kelly, AL; Rhodes, DA; Roland, JM; Schofield, P, 1998) |
| "A case of severe cardiac failure due to iron overload in a patient with beta-thalassemia major is reported." | 1.29 | Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major. ( Balmer-Ruedin, D; Halperin, DS; Oberhansli, I; Wacker, P; Wyss, M, 1993) |
| "Dobutamine is a sympathomimetic drug (beta 1 agonist) that increases myocardial contractility and at high doses also systolic arterial blood pressure and heart rate." | 1.29 | Cardiac study by dobutamine stress echocardiography in thalassemic patients. ( Agostini, A; Angelucci, E; Cesaroni, P; Lucarelli, G; Mariotti, E; Sgarbi, E, 1993) |
| "Severe congestive cardiac failure developed in a few weeks in a 44 year old man who had undergone porto-caval anastamosis for post-hepatitis cirrhosis one year previously and then treated for anaemia by repeated blood transfusion and chronic daily oral iron therapy." | 1.27 | [Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent]. ( Azancot, I; Baudouy, P; Lombrail, P; Martin, E; Piekarski, A; Slama, R, 1983) |
| "Idiopathic hemochromatosis is an iron-storage disease more common in men than in women." | 1.26 | Idiopathic hemochromatosis: case report of a patient presenting with neurologic symptoms. ( Afrooz, N; Sinclair, WP, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (31.91) | 18.7374 |
| 1990's | 6 (12.77) | 18.2507 |
| 2000's | 19 (40.43) | 29.6817 |
| 2010's | 5 (10.64) | 24.3611 |
| 2020's | 2 (4.26) | 2.80 |
| Authors | Studies |
|---|---|
| Chuang, TY | 1 |
| Li, JP | 1 |
| Weng, TF | 1 |
| Wu, KH | 4 |
| Chao, YH | 1 |
| Johnson, AC | 1 |
| Zager, RA | 1 |
| Cooray, SD | 1 |
| Heerasing, NM | 1 |
| Selkrig, LA | 1 |
| Subramaniam, VN | 1 |
| Hamblin, PS | 1 |
| McDonald, CJ | 1 |
| McLean, CA | 1 |
| McNamara, E | 1 |
| Leet, AS | 1 |
| Roberts, SK | 1 |
| Porter, JB | 1 |
| Wood, J | 1 |
| Olivieri, N | 1 |
| Vichinsky, EP | 1 |
| Taher, A | 1 |
| Neufeld, E | 1 |
| Giardina, P | 1 |
| Thompson, A | 1 |
| Moore, B | 1 |
| Evans, P | 1 |
| Kim, HY | 1 |
| Macklin, EA | 1 |
| Trachtenberg, F | 1 |
| Origa, R | 1 |
| Danjou, F | 1 |
| Cossa, S | 1 |
| Matta, G | 1 |
| Bina, P | 1 |
| Dessì, C | 2 |
| Defraia, E | 1 |
| Foschini, ML | 1 |
| Leoni, G | 1 |
| Morittu, M | 1 |
| Galanello, R | 2 |
| Tauchenová, L | 1 |
| Křížová, B | 1 |
| Kubánek, M | 1 |
| Fraňková, S | 1 |
| Melenovský, V | 1 |
| Tintěra, J | 1 |
| Kautznerová, D | 1 |
| Malušková, J | 1 |
| Jirsa, M | 1 |
| Kautzner, J | 1 |
| Peng, CT | 3 |
| Chang, JS | 3 |
| Tsai, CH | 2 |
| Lin, HS | 1 |
| Omiya, S | 1 |
| Hikoso, S | 1 |
| Imanishi, Y | 1 |
| Saito, A | 1 |
| Yamaguchi, O | 1 |
| Takeda, T | 1 |
| Mizote, I | 1 |
| Oka, T | 1 |
| Taneike, M | 1 |
| Nakano, Y | 1 |
| Matsumura, Y | 1 |
| Nishida, K | 1 |
| Sawa, Y | 1 |
| Hori, M | 1 |
| Otsu, K | 1 |
| Cassinerio, E | 1 |
| Roghi, A | 1 |
| Pedrotti, P | 1 |
| Brevi, F | 1 |
| Zanaboni, L | 1 |
| Graziadei, G | 1 |
| Pattoneri, P | 1 |
| Milazzo, A | 1 |
| Cappellini, MD | 3 |
| SCOVILLE, B | 1 |
| BORCHERS, HG | 1 |
| SCHAUER, A | 1 |
| Yang, T | 1 |
| Brittenham, GM | 1 |
| Dong, WQ | 1 |
| Levy, MN | 1 |
| Obejero-Paz, CA | 1 |
| Kuryshev, YA | 1 |
| Brown, AM | 1 |
| Erfurth, EM | 1 |
| Holmer, H | 1 |
| Nilsson, PG | 1 |
| Kornhall, B | 1 |
| Aessopos, A | 3 |
| Farmakis, D | 3 |
| Hatziliami, A | 1 |
| Fragodimitri, C | 1 |
| Karabatsos, F | 1 |
| Joussef, J | 1 |
| Mitilineou, E | 1 |
| Diamanti-Kandaraki, E | 1 |
| Meletis, J | 2 |
| Karagiorga, M | 1 |
| Borgna-Pignatti, C | 1 |
| Rugolotto, S | 1 |
| De Stefano, P | 1 |
| Zhao, H | 1 |
| Del Vecchio, GC | 1 |
| Romeo, MA | 1 |
| Forni, GL | 1 |
| Gamberini, MR | 1 |
| Ghilardi, R | 1 |
| Piga, A | 1 |
| Cnaan, A | 1 |
| Tsironi, M | 2 |
| Deftereos, S | 2 |
| Andriopoulos, P | 2 |
| Polonifi, K | 1 |
| Moyssakis, I | 1 |
| Pennell, DJ | 2 |
| Martín, M | 1 |
| Estornell, J | 1 |
| Orero, M | 1 |
| Pérez, JL | 1 |
| Ridocci, F | 1 |
| Martínez, V | 1 |
| Tavecchia, L | 1 |
| Masera, N | 1 |
| Russo, P | 1 |
| Cirò, A | 1 |
| Vincenzi, A | 1 |
| Vimercati, C | 1 |
| Masera, G | 1 |
| Kolnagou, A | 2 |
| Economides, C | 1 |
| Eracleous, E | 1 |
| Kontoghiorghes, GJ | 2 |
| Huang, YC | 1 |
| Fabio, G | 1 |
| Minonzio, F | 1 |
| Delbini, P | 1 |
| Bianchi, A | 1 |
| Templin, C | 1 |
| Pertschy, S | 1 |
| Schaefer, A | 1 |
| Tanner, MA | 1 |
| Smith, GC | 1 |
| Westwood, MA | 1 |
| Agus, A | 1 |
| Roughton, M | 1 |
| Assomull, R | 1 |
| Nair, SV | 1 |
| Walker, JM | 1 |
| Kondur, AK | 1 |
| Li, T | 1 |
| Vaitkevicius, P | 1 |
| Afonso, L | 1 |
| Bannerman, RM | 1 |
| Keusch, G | 1 |
| Kreimer-Birnbaum, M | 1 |
| Vance, VK | 1 |
| Vaughan, S | 1 |
| Baudouy, P | 1 |
| Lombrail, P | 1 |
| Azancot, I | 1 |
| Piekarski, A | 1 |
| Martin, E | 1 |
| Slama, R | 1 |
| Nienhuis, AW | 2 |
| Griffith, P | 1 |
| Strawczynski, H | 1 |
| Henry, W | 2 |
| Borer, J | 1 |
| Leon, M | 1 |
| Anderson, WF | 1 |
| Pisano, GF | 1 |
| Binaghi, F | 1 |
| Putzu, ML | 1 |
| Bragotti, R | 1 |
| Manconi, E | 1 |
| Urgu, G | 1 |
| Pitzus, F | 1 |
| Hou, JW | 1 |
| Wu, MH | 1 |
| Lin, KH | 1 |
| Lue, HC | 1 |
| Wacker, P | 1 |
| Halperin, DS | 1 |
| Balmer-Ruedin, D | 1 |
| Oberhansli, I | 1 |
| Wyss, M | 1 |
| Mariotti, E | 1 |
| Agostini, A | 1 |
| Angelucci, E | 1 |
| Cesaroni, P | 1 |
| Lucarelli, G | 1 |
| Sgarbi, E | 1 |
| Kelly, AL | 1 |
| Rhodes, DA | 1 |
| Roland, JM | 1 |
| Schofield, P | 1 |
| Cox, TM | 1 |
| Young, N | 1 |
| Sinclair, WP | 1 |
| Afrooz, N | 1 |
| de Montalembert, M | 1 |
| Jan, D | 1 |
| Clairicia, M | 1 |
| Hannedouche, T | 1 |
| Sidi, D | 1 |
| Girot, R | 1 |
| Tiede, R | 1 |
| Sareen, S | 1 |
| Singal, PK | 1 |
| Freeman, AP | 1 |
| Giles, RW | 1 |
| Berdoukas, VA | 1 |
| Talley, PA | 1 |
| Murray, IP | 1 |
| Rahko, PS | 1 |
| Salerni, R | 1 |
| Uretsky, BF | 1 |
| Festa, RS | 1 |
| Kanz, L | 1 |
| Arnold, H | 1 |
| Löhr, GW | 1 |
| Mancuso, L | 1 |
| Iacona, MA | 1 |
| Marchi, S | 1 |
| Rigano, P | 1 |
| Geraci, E | 1 |
| Seshadri, R | 1 |
| Colebatch, JH | 1 |
| Gordon, P | 1 |
| Ekert, H | 1 |
| Giorgio, AJ | 1 |
| Lukens, JN | 1 |
| Neuman, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [NCT00000595] | Phase 2 | 0 participants | Interventional | 1978-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for deferoxamine and Cardiac Failure
| Article | Year |
|---|---|
Mechanisms of and obstacles to iron cardiomyopathy in thalassemia.
Topics: Blood Pressure; Cardiomyopathies; Deferoxamine; Electrocardiography; Heart; Heart Failure; Humans; I | 2008 |
T2* magnetic resonance and myocardial iron in thalassemia.
Topics: Adult; Calibration; Cardiomyopathies; Chelation Therapy; Child; Cohort Studies; Combined Modality Th | 2005 |
Quantification of myocardial iron overload by cardiovascular magnetic resonance imaging T2* and review of the literature.
Topics: Animals; Cardiomyopathies; Deferoxamine; Early Diagnosis; Female; Heart Failure; Hemosiderosis; Huma | 2009 |
Modern management of thalassemia.
Topics: Adolescent; Arrhythmias, Cardiac; Ascorbic Acid; Blood Transfusion; Child; Cholelithiasis; Deferoxam | 1985 |
4 trials available for deferoxamine and Cardiac Failure
| Article | Year |
|---|---|
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Heart Failure | 2013 |
Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Comorbidity; Deferasirox; Deferiprone; Deferoxamine; Drug Therap | 2012 |
Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Topics: Administration, Oral; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Clinical Protocols; Com | 2006 |
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2007 |
39 other studies available for deferoxamine and Cardiac Failure
| Article | Year |
|---|---|
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
Topics: Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Drug Evaluati | 2020 |
Catalytic iron mediated renal stress responses during experimental cardiorenal syndrome 1 ("CRS-1").
Topics: Animals; Biomarkers; Cardio-Renal Syndrome; Cell Line; Deferoxamine; Gene Expression Regulation; Hea | 2021 |
Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report.
Topics: Adult; Biopsy; Chelation Therapy; Deferoxamine; Echocardiography; Ferritins; Heart Failure; Heart Ve | 2018 |
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Defer | 2013 |
Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone.
Topics: Cardiomyopathies; Deferiprone; Deferoxamine; Ferritins; Heart Failure; Hemochromatosis; Hemochromato | 2016 |
Downregulation of ferritin heavy chain increases labile iron pool, oxidative stress and cell death in cardiomyocytes.
Topics: Animals; Antioxidants; Aorta; Apoferritins; Chelating Agents; Deferoxamine; Down-Regulation; Ferrocy | 2009 |
[ERYTHROBLASTOPHTHISIS].
Topics: Adrenal Cortex Hormones; Androgens; Blood Cell Count; Blood Transfusion; Deferoxamine; Electrocardio | 1964 |
Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Deferoxamine; Female; Gerbillinae; Heart Failure; Iron; Iro | 2003 |
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; D | 2004 |
Is growth hormone deficiency contributing to heart failure in patients with beta-thalassemia major?
Topics: Adult; beta-Thalassemia; Cardiotonic Agents; Deferoxamine; Female; Heart Failure; Human Growth Hormo | 2004 |
Cardiac status in well-treated patients with thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Cardiac Output; Child; Deferoxamine; Echocar | 2004 |
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Topics: Adult; Age Factors; Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Cohort Studies; Defe | 2004 |
Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Synergism; Drug Therapy, Combination; Heart | 2005 |
Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferiprone; Def | 2005 |
[Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Heart Failure; Humans; Iron C | 2006 |
Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Failure; Hemosi | 2006 |
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiomyopathies; Chelation Therapy; Combined Mod | 2006 |
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomegaly; Cardiomyopathies; Chelation Therapy; Cohort Studi | 2006 |
Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH).
Topics: Adult; Amino Acid Substitution; Antimicrobial Cationic Peptides; Atrial Fibrillation; Chelation Ther | 2007 |
Cardiac hemochromatosis.
Topics: Deferoxamine; Erythrocyte Transfusion; Fatal Outcome; Female; Heart Diseases; Heart Failure; Hemochr | 2007 |
Thalassemia intermedia, with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyrinuria.
Topics: Adult; Blood Transfusion; Deferoxamine; Diabetes Mellitus; Folic Acid; Folic Acid Deficiency; Heart | 1967 |
[Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent].
Topics: Adult; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Deferoxamine; Diastole; Echocardiography; Elec | 1983 |
Evaluation of cardiac function in patients with thalassemia major.
Topics: Adolescent; Adult; Ascorbic Acid; Child; Child, Preschool; Deferoxamine; Heart; Heart Diseases; Hear | 1980 |
[Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
Topics: Adolescent; Adult; Cardiomyopathies; Child; Child, Preschool; Deferoxamine; Echocardiography; Electr | 1981 |
Prognostic significance of left ventricular diastolic indexes in beta-thalassemia major.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Child; Child, Preschool; Deferoxamine; Diastole; E | 1994 |
Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major.
Topics: Adult; Ambulatory Care; beta-Thalassemia; Deferoxamine; Echocardiography; Heart Failure; Humans; Inf | 1993 |
Cardiac study by dobutamine stress echocardiography in thalassemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modality Therapy; Deferoxami | 1993 |
Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease.
Topics: Adolescent; Adult; Age of Onset; Chelating Agents; Deferoxamine; Endocrine System Diseases; Female; | 1998 |
Treatment of primary hemochromatosis with deferoxamine.
Topics: Adult; Arrhythmias, Cardiac; Deferoxamine; Female; Heart Failure; Hemochromatosis; Humans; Male; Ped | 1979 |
Idiopathic hemochromatosis: case report of a patient presenting with neurologic symptoms.
Topics: Aged; Deferoxamine; Diabetes Mellitus; Female; Heart Failure; Hemochromatosis; Humans; Iron; Liver C | 1977 |
[Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-A-Cath)].
Topics: Acute-Phase Reaction; Adolescent; Adult; Catheters, Indwelling; Deferoxamine; Female; Heart Failure; | 1992 |
Transferrin delays oxygen radical induced cardiac-contractile failure.
Topics: Animals; Basement Membrane; Deferoxamine; Free Radicals; Heart Failure; Lipid Peroxidation; Male; Ma | 1990 |
Sustained normalization of cardiac function by chelation therapy in thalassaemia major.
Topics: Adolescent; Adult; Australia; Blood Transfusion; Chelation Therapy; Child; Combined Modality Therapy | 1989 |
Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload.
Topics: Adult; Anemia, Macrocytic; Anemia, Megaloblastic; Deferoxamine; Diabetes Complications; Echocardiogr | 1986 |
High-dose desferoxamine and Diamond-Blackfan anemia.
Topics: Adolescent; Anemia; Deferoxamine; Heart Failure; Humans; Infusions, Parenteral; Thalassemia; Transfu | 1986 |
[Severe cardiomyopathy in a woman with intermediate beta-thalassemia. Regression of cardiac failure with desferrioxamine].
Topics: Adult; Deferoxamine; Echocardiography; Electrocardiography; Female; Heart Failure; Humans; Thalassem | 1985 |
Long-term administration of desferrioxamine in thalassaemia major.
Topics: Adolescent; Adult; Aspartate Aminotransferases; Bilirubin; Blood Protein Electrophoresis; Blood Tran | 1974 |
Primary hemochromatosis: easily missed cause of cirrhosis, diabetes and heart failure.
Topics: Age Factors; Aged; Blood Cell Count; Bloodletting; Deferoxamine; Diabetes Mellitus; Female; Heart Fa | 1973 |
EXcretion and distribution of iron during chronic deferoxamine therapy.
Topics: Anemia, Aplastic; Bone Marrow; Bone Marrow Examination; Child; Chromium Isotopes; Deferoxamine; Foli | 1971 |